The Clinical Urgency
Suicide claims over 700,000 lives annually worldwide. Among the most critical gaps in psychiatric care is the absence of pharmacological interventions that rapidly reduce suicidal ideation (SI). Conventional antidepressants carry FDA black-box warnings for potential suicidality increases in younger populations, and their therapeutic onset is measured in weeks. Low-dose ketamine as a rapid-acting intervention for acute SI represents a potentially transformative development in crisis psychiatry.
Foundational Clinical Evidence
DiazGranados et al. (2010)
One of the earliest controlled investigations of ketamine's anti-suicidal effects was conducted by DiazGranados and colleagues at the NIMH, published in the Journal of Clinical Psychiatry. In this study, 33 patients with treatment-resistant MDD received a single intravenous infusion of ketamine (0.5 mg/kg over 40 minutes) or saline placebo in a crossover design. Using the Scale for Suicide Ideation (SSI), the investigators found that ketamine produced significant reductions in SI within 40 minutes of infusion onset, with effects persisting through 4 hours. Notably, the anti-suicidal effect remained significant after controlling for concurrent changes in overall depression severity, suggesting a partially independent mechanism.
Price et al. (2009, 2014)
Price and colleagues provided further evidence through secondary analyses of NIMH ketamine trial data. Their 2014 analysis published in Biological Psychiatry examined SI trajectories in 133 patients across multiple studies. They confirmed that ketamine rapidly reduced SI compared to placebo and reported that the anti-suicidal effect was partially, but not fully, mediated by improvements in depression, anxiety, and hopelessness. This finding raises the intriguing possibility that ketamine exerts specific anti-suicidal mechanisms beyond general antidepressant action, potentially through neuroplasticity pathways.
Randomized Controlled Trials
Murrough et al. (2015) --- Midazolam-Controlled Trial
Murrough and colleagues published a landmark RCT in the American Journal of Psychiatry comparing single-dose intravenous ketamine to midazolam (an active control) in 24 patients with clinically significant SI. At 24 hours, ketamine produced significantly greater reductions in SI as measured by the SSI and the Beck Scale for Suicide Ideation (BSI). The use of midazolam as an active control helps preserve blinding by producing sedation and mild psychoactive effects.
Grunebaum et al. (2018) --- Midazolam-Controlled Trial in MDD
Grunebaum et al. conducted an RCT published in the American Journal of Psychiatry involving 80 adults with MDD and clinically significant SI. Patients received ketamine (0.5 mg/kg) or midazolam (0.02 mg/kg). Ketamine was significantly superior, with a between-group effect size of Cohen's d = 0.75. Approximately 55% of ketamine-treated patients achieved clinically meaningful SI reduction at 24 hours compared to 30% in the midazolam group.
Ionescu et al. (2019) --- Repeated Infusions
Ionescu et al., publishing in the Journal of Clinical Psychiatry, examined repeated ketamine infusions (six over three weeks) in patients with TRD and persistent SI. Results demonstrated progressive SI reductions with successive infusions, with a substantial proportion achieving remission by the end of the treatment course.
Emergency Department and Inpatient Studies
Emergency Department Protocols
Kashani et al. (2014) conducted one of the first studies evaluating low-dose ketamine in the emergency department setting. Published in Academic Emergency Medicine, this pilot study administered ketamine (0.2 mg/kg bolus) to patients presenting with acute SI, observing significant reductions within 40 minutes that persisted through a 10-day follow-up. Subsequent studies by Burger et al. (2016) and Domany et al. (2019) reinforced these findings, with Domany's randomized, double-blind, placebo-controlled trial demonstrating significant ketamine superiority for SI reduction at 90 and 180 minutes post-infusion.
Mechanisms Specific to Anti-Suicidal Effects
Beyond Depression Reduction
A consistent finding across studies is that ketamine's anti-suicidal effect is not fully explained by its antidepressant action. Statistical mediation analyses suggest that while depression reduction accounts for a portion of the SI improvement, a significant direct effect persists after controlling for depressive symptom change. Candidate mechanisms for this independent anti-suicidal action include rapid reduction in psychological pain, decreased hopelessness, improved cognitive flexibility, and enhanced executive function --- all of which are impaired in suicidal states and are associated with PFC dysfunction.
Opioid System Involvement
Williams et al. (2018), publishing in the American Journal of Psychiatry, investigated whether ketamine's effects involve the opioid system by pretreating patients with naltrexone. Naltrexone attenuated ketamine's antidepressant effects, suggesting partial opioid system involvement --- a finding with implications for both mechanism and abuse liability that warrants further replication.
Safety and Ethical Considerations
In supervised clinical settings, low-dose ketamine has demonstrated an acceptable acute safety profile. Common side effects include transient dissociation, dizziness, nausea, and mild hemodynamic changes, all typically resolving within 1 to 2 hours. Administration to acutely suicidal patients raises ethical considerations regarding informed consent capacity. Clinical protocols typically require monitored observation for at least 2 hours post-infusion and confirmed follow-up psychiatric care before discharge.
Future Directions
Large-scale, multisite RCTs examining repeated ketamine dosing for SI in diverse clinical settings --- including emergency departments, inpatient psychiatric units, and military populations --- are needed to establish definitive efficacy and safety data. Integration of ketamine with safety planning interventions, crisis counseling, and transition to maintenance treatments represents a promising model for comprehensive suicide prevention care.
References
- NIMH: Suicide Prevention — National Institute of Mental Health information on suicide prevention research, risk factors, and warning signs
- 988 Suicide and Crisis Lifeline — National crisis support resource providing free, confidential emotional support 24/7
- PubMed: Ketamine for Suicidal Ideation: Systematic Review and Meta-Analysis — Meta-analysis of treatment trials examining ketamine's efficacy for reducing suicidal ideation
- PubMed: Ketamine for Acute Treatment of Severe Suicidal Ideation: Double-Blind RCT — Randomized placebo-controlled trial of ketamine for acute suicidal ideation
- SAMHSA: Substance Abuse and Mental Health Services Administration — Federal agency providing resources on mental health crisis intervention and substance abuse services
Share